MET — Targeted Therapies, Trials & Pipeline
MET exon 14 skipping and amplification drive a targetable NSCLC subset; also a resistance mechanism to EGFR therapy.
MET exon 14 skipping and amplification drive a targetable NSCLC subset; also a resistance mechanism to EGFR therapy.